- Home
- TWLO vs ROIV Comparison
TWLO vs ROIV Comparison
Compare TWLO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWLO
- ROIV
- Stock Information
- Founded
- TWLO 2008
- ROIV 2014
- Country
- TWLO United States
- ROIV United Kingdom
- Employees
- TWLO N/A
- ROIV N/A
- Industry
- TWLO Computer Software: Prepackaged Software
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- TWLO Technology
- ROIV Health Care
- Exchange
- TWLO Nasdaq
- ROIV Nasdaq
- Market Cap
- TWLO 16.7B
- ROIV 14.0B
- IPO Year
- TWLO 2016
- ROIV N/A
- Fundamental
- Price
- TWLO $125.15
- ROIV $20.65
- Analyst Decision
- TWLO Buy
- ROIV Strong Buy
- Analyst Count
- TWLO 26
- ROIV 8
- Target Price
- TWLO $139.08
- ROIV $21.19
- AVG Volume (30 Days)
- TWLO 2.3M
- ROIV 9.3M
- Earning Date
- TWLO 10-30-2025
- ROIV 11-10-2025
- Dividend Yield
- TWLO N/A
- ROIV N/A
- EPS Growth
- TWLO N/A
- ROIV N/A
- EPS
- TWLO 0.43
- ROIV N/A
- Revenue
- TWLO $4,896,125,000.00
- ROIV $20,329,000.00
- Revenue This Year
- TWLO $14.56
- ROIV N/A
- Revenue Next Year
- TWLO $8.77
- ROIV $320.50
- P/E Ratio
- TWLO $291.08
- ROIV N/A
- Revenue Growth
- TWLO 12.84
- ROIV N/A
- 52 Week Low
- TWLO $77.51
- ROIV $8.73
- 52 Week High
- TWLO $151.95
- ROIV $21.35
- Technical
- Relative Strength Index (RSI)
- TWLO 56.37
- ROIV 69.21
- Support Level
- TWLO $123.02
- ROIV $19.79
- Resistance Level
- TWLO $132.44
- ROIV $21.33
- Average True Range (ATR)
- TWLO 4.82
- ROIV 0.74
- MACD
- TWLO 0.14
- ROIV 0.02
- Stochastic Oscillator
- TWLO 53.81
- ROIV 74.84
About TWLO Twilio Inc.
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.